Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Extendryl GCP
- Development stage
- Unknown
- Lead developer
- Auriga Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Extendryl GCP is a combination pharmaceutical product containing carbetapentane (also known as pentoxyverine), guaifenesin, and phenylephrine. It is indicated for the symptomatic relief of cough, nasal congestion, and chest congestion associated with the common cold, sinusitis, or upper respiratory allergies. Carbetapentane acts as a non-opioid antitussive by suppressing the cough reflex in the brain, primarily through sigma-1 receptor agonism and muscarinic antagonism. Guaifenesin is an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi, facilitating their removal. Phenylephrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction in the nasal mucosa. The product has been available in various oral forms, including extended-release tablets and liquids.
- Brand names
- Extendryl GCP
- Other names
- carbetapentane + guaifenesin + phenylephrine
02
Targets
ADRA1A (α1A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on Extendryl GCP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Extendryl GCP.